Articles tagged with Prostate Tumors
Researchers at UNC Lineberger Comprehensive Cancer Center found a new protein SFRP2 that stimulates angiogenesis in various tumor sites. The discovery provides a potential target for developing new drugs to starve tumors of blood supply and destroy them.
A recent study found that men with low oxygen levels in their prostate tumor are more likely to experience a return of prostate cancer after treatment. Researchers say this finding could lead to personalized treatment approaches, including combination therapies and non-invasive methods for detecting oxygen levels in tumors.
A recent study found that carbohydrate restriction without weight loss can slow prostate tumor growth by lowering serum insulin levels. The researchers believe that this mechanism is key to fighting prostate cancer growth and potentially improving patient outcomes.
Researchers created a mathematical formula that incorporated equations describing tumor evolution and growth, predicting oxygen consumption rates and cell growth. The computational model was validated with human brain tumor samples and successfully mimicked natural biological tumors.
Researchers at University of Cincinnati have identified a new molecular pathway responsible for the rapid development of invasive prostate cancer tumors. The simultaneous inactivation of PTEN and Par-4 genes causes a synergistic effect leading to more aggressive tumors.
Researchers at Fox Chase Cancer Center found that low-oxygen regions in prostate tumors are associated with increased PSA levels, a marker of tumor recurrence. The study used a custom-built probe to monitor oxygen levels in tumors and non-cancerous muscle tissue before localized radiation therapy.
A study by Japanese researchers found that a molecule called M-CSF can be used to block the formation of new blood vessels in tumors, suppressing growth even after treatment is stopped. This approach differs from existing VEGF-based treatments, which have been shown to have limited long-term effects.
Researchers found a 72% reduction in risk for tumor inflammation among men taking statins, which may contribute to lower advanced prostate cancer incidence. Statin use could potentially control or prevent prostate cancer through anti-inflammatory effects.
Researchers have engineered a new version of the tumour-inhibiting protein VHL that can target hypoxic areas in tumours, reducing HIF levels and causing tumours to regress. This breakthrough has implications for treating various types of cancer, particularly those resistant to conventional therapies.
A major US study of 75,000 men found that annual prostate cancer screening led to more diagnoses but not fewer deaths. The study suggests that men with a short life expectancy may not need screening, and further research is needed to determine its benefits and harms.
Whitehead Institute researchers have identified a cellular pathway that determines whether cancerous tumors are susceptible to dietary restriction. The study found that permanently activated PI3K pathway allows tumors to grow independent of food consumption, while normal functioning leads to tumor shrinkage.
Focal cryoablation, a minimally invasive treatment, is as effective as surgery in destroying diseased tumors and can be considered a first-line treatment for patients of all risk levels. The use of 3-D transperineal mapping biopsy heavily impacted how patients' disease was managed in 70 percent of cases.
Research suggests that lowering cholesterol levels can block the growth of prostate tumors and reduce cancer incidence. Ezetimibe, a cholesterol-lowering drug, has been shown to inhibit tumor angiogenesis, promoting less aggressive tumors.
Research isolated a subset of pancreatic cancer cells expressing CD44 and CD24, which exhibit lower proliferative index and faster tumor growth rate. Further purification is needed to understand their biological behaviors.
A new study reveals that tumor blood vessel cells have the potential to differentiate into cartilage- or bone-like tissues, making them remarkably atypical. The research also found that these cells can undergo calcification, a process that may facilitate metastasis and tumor cell entry into the bloodstream.
Abnormal tumor blood vessels are 'leaky' and 'twisty', hindering chemotherapy drug delivery. Researchers identify a key factor: tumor capillary cells' inability to sense mechanical forces, leading to irregular vessel formation. Normalizing these forces may improve therapy effectiveness.
Scientists at Dana-Farber Cancer Institute discovered that blocking p110beta molecule inhibits prostate tumor growth, suggesting it as a potential target for novel cancer therapies. The study, published in Nature, reveals p110beta's role in driving runaway cell growth when PTEN function is impaired.
Researchers found that metastatic prostate tumors produce significant levels of testosterone, fueling cancer growth despite low circulating androgen levels. This discovery suggests targeting the tumor itself, rather than systemic hormone suppression, to develop more effective treatments for all stages of prostate cancer.
Researchers found that FruHis, a carbohydrate in dehydrated tomato products, has strong protective effects against prostate cancer. The study shows that a diet rich in tomato paste and FruHis led to the longest survival rate among rats with prostate cancer.
A re-analysis of PCPT data reveals that finasteride significantly reduces the incidence of prostate cancers, including higher-grade ones. The study also suggests that finasteride may suppress indolent cancers and could be useful in determining tumor aggressiveness.
Only a small proportion of diagnosed low-risk prostate cancers will progress to life-threatening disease during a patient's lifetime. Recorded incidence has increased due to screening and improved diagnosis, but mortality rates have not kept pace, suggesting that most low-risk cases may remain stable or even decrease over time.
A new study suggests that therapies inhibiting IGF-1 signaling in prostate cancer may not work as expected in tumors with a compromised p53 gene. The research, conducted by investigators at Fred Hutchinson Cancer Center, found that eliminating IGF-1R expression led to hyperplastic cell growth and proliferation in mouse prostates.
A study by researchers at Duke University Medical Center found that exercising mice grew prostate tumors twice as fast as non-exercising mice, potentially leading to improved drug delivery models for cancer treatment. The exercise may increase blood flow to tumors, allowing for better distribution of medicine.
A recent study found that 3T MRI without an endorectal coil can detect prostate cancer with diagnostic image quality and accurate tumor localization. The technique provided undistorted images of the prostate and surrounding tissue, allowing for precise surgical planning.
Researchers at UT Southwestern Medical Center have found that arsenic linked to a cancer-homing drug provides a powerful imaging agent for detecting hard-to-find tumors. The technique allows physicians to detect early tumor deposits and monitor cancer's response to therapy with clear images.
A study found that 46% of patients received a maximum dose above 10% beyond the prescribed level, while 63% got a minimum dose below 10%, highlighting the need for standardization in intensity-modulated radiation therapy.
Researchers at Vanderbilt University Medical Center have identified a small protein that specifically recognizes tumors responding to chemotherapy, allowing for rapid visualization of cancer response in mice. This breakthrough could enable more efficient treatment customization and accelerate the development of new cancer drugs.
Immune cells can detect prostate cancer using a specific receptor on T cells, which recognizes the cancerous tumor. The molecular signpost is histone H4, a protein found in all cells but displayed only on the surface of tumor cells.
A microchip-based device, called the CTC-chip, can isolate, enumerate, and analyze circulating tumor cells from blood samples. The device was tested on 68 patients with five different types of tumors and showed a sensitivity rating of 99%, accurately monitoring response to treatment.
A team of researchers has discovered a tumor-suppressor gene called Par-4 that kills cancer cells but not normal cells. The mice born with this gene live longer and have no toxic side effects, making it a potentially therapeutic application for treating cancer without harming patients.
A low-carb diet may help stunt prostate tumor growth by reducing insulin production, according to a new study. The study found that mice on a low-carb diet had longer survival and smaller tumors than those on other diets.
A team of researchers found that SENP1 regulates the entire hypoxic response and plays a role in other kinds of cancers. Inhibiting SENP1 might be one way to turn off tumor growth by cutting off a protein's ability to build new blood vessels.
Scientists at Newcastle University have developed a technology using UV light to activate antibodies specifically targeting tumour cells. The cloaked antibodies can be used alone or in combination with existing antibodies, minimizing side effects and maximizing destruction of tumours.
Men with Gleason score 7 and tertiary grade 5 disease have a shorter time to PSA failure than those with Gleason score 8-10. This finding may affect management of care for men with prostate cancer.
Italian scientists have discovered a new target for anti-tumor therapy in cancer, finding that the Trop-2 gene is expressed in the vast majority of human cancers. The gene's over-expression was found in between 65% and 90% of tumor types analyzed.
Researchers have developed a new non-invasive prenatal testing method that analyzes mother's blood to detect fetal mRNAs, which could be used for prenatal diagnosis of genetic diseases. In another study, mice exposed to particulate matter were found to have accelerated blood clotting and thrombosis, highlighting the need to target IL-6...
A University of Minnesota study found no evidence that prostate cancer is more aggressive in black men, contradicting previous studies. The research matched patients by age, Gleason grade, clinical stage, and PSA levels before prostatectomy.
Two studies found that finasteride reduces prostate cancer incidence, but increases detection of high-grade cancers. Analysis suggests increased detection rather than development of high-grade cancers. The findings have favorable implications for the clinical impact of finasteride.
A new study found that taking folic acid supplements does not reduce the risk of developing precancerous colon tumors and may even increase it. Researchers also suggest that fortification of grain-based foods with folic acid may be a contributing factor to increased risk.
Researchers at Institut Gustave Roussy found that a combination of radiation and angiogenesis inhibitors can overcome HIF-1–dependent tumor radioresistance in mice. This breakthrough suggests a new approach to treating cancer by shifting tumor resistance towards apoptosis, according to the study published online on June 7.
Researchers at VCU's Massey Cancer Center are developing a new form of radiation therapy that can safely administer more aggressive cancer treatments. The project aims to enhance the safety and effectiveness of current treatments by incorporating quantitative and predictive image analysis.
A new imaging method measures water diffusion in tumors to detect early response to treatment for advanced prostate cancer. Researchers found that changes in water diffusion could predict tumor response to chemotherapy as early as seven days after treatment began.
Alan Garen and Zhiwei Hu have developed a way to target and destroy tumor blood vessels using nanoparticles. The technology uses a synthetic gene that activates an immune response, allowing for selective destruction of tumors while leaving normal tissue unharmed.
Researchers have successfully targeted the blood vessels that feed tumors, providing a new approach to treating cancer. The study used an antibody called J591 that selectively targets prostate-specific membrane antigen (PSMA) on tumors and not healthy tissues.
A University of Illinois study reveals that combining tomatoes and broccoli in the diet can effectively reduce prostate tumors. The study found that eating both foods together produces an additive effect, with tumor cells proliferating more slowly.
A new 'inverse planning' system developed by the Georgia Institute of Technology improves brachytherapy treatment for prostate and other cancers. The system optimizes radiation doses to tumor cells while minimizing effects on nearby structures, leading to better local tumor control and reduced side effects.
Researchers discovered a novel 'Trojan Horse' agent, VEGF121/rGel, that completely prevented bone tumor development in 50% of mice. The agent stops specialized cells within the bone from chewing up bone material to make room for implanted tumors to grow.
Researchers at Thomas Jefferson University have found that the protein fragment endorepellin blocks both skin and lung cancer tumors from progressing in animal models by preventing their ability to recruit new blood vessels. Endorepellin has surprisingly powerful effects on halting a cancer tumor's ability to move about and spread.
Researchers found a correlation between tNOX levels and tumor burden in prostate cancer patients, suggesting its potential as a reliable biomarker. The study showed that tNOX levels increased with disease progression and were more uniform in terms of disease severity than PSA scores.
Researchers discover a three-drug combo that inhibits the growth of aggressive prostate tumors by targeting neural signaling molecules and energy sources. The combination, using diuretic amiloride, Parkinson's disease medication carbidopa, and sedative-reversal drug flumazenil, shows promise for potential therapeutic applications.
Researchers discovered that overexpressing a gene called uPA in mammary cancer cells can delay tumor progression and inhibit the formation of new blood vessels, leading to slower tumor growth. The study also suggests that uPA expression may have anti-cancer effects by reducing angiogenesis and proliferation.
Researchers found that cancer treatment effectiveness is independent of tumor type, and varying levels of specific proteins determine drug response. This study suggests a new approach to treating cancer by selecting therapies tailored for individual patients instead of one-size-fits-all approaches.
Phenethyl-ITC, a phytochemical found in cruciferous vegetables, has been shown to suppress the growth of human prostate cancer cells. Mice grafted with human prostate tumors and administered PEITC daily exhibited significantly reduced tumor volume compared to controls.
Researchers detected a novel virus, XMRV, in human prostate tumors with two copies of the RNASEL gene mutation. The study validates the use of DNA-hunting 'virus chip' technology to discover previously unknown viruses and potentially uncover new viral causes for disease.
Research reveals omega-6 fatty acids stimulate inflammatory genes associated with cancer, particularly in prostate tumors. Studies found that adding omega-6 to growth medium doubled tumor growth compared to control groups.
Researchers found that the combination of curcumin and PEITC significantly retards prostate cancer tumor growth in laboratory mice. The discovery suggests potential for using plant-based compounds as alternative therapies to treat advanced prostate cancers.
A study found that Ack1 is a key driver of tumor growth in prostate cancer, and its inhibition can slow tumor formation. The researchers also discovered an experimental drug called geldanamycin that can inhibit Ack1 activity by interfering with its molecular interactions.
A study by Case Western Reserve University researchers found that apigenin, a plant flavonoid, slowed tumor growth in mice with prostate cancer. Apigenin also reduced IGF-1 levels associated with increased cancer risk and triggered cell self-destruction.
Researchers found ER-positive/PR-negative tumors may be more aggressive and respond poorly to tamoxifen, while EDNRB mutations are linked to melanoma risk. Farnesyltransferase inhibitors show promise against aerodigestive tract cancer cells.
A study found that nearly 60% of prostate cancer specimens received higher Gleason scores than original assignments, suggesting that pathologists are more likely to assign high scores to contemporary tumor samples. This 'Will Rogers phenomenon' may lead to a false sense of therapeutic accomplishment and skew mortality rates.